thalidomide has been researched along with sirolimus in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, KC; Antin, JH; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, S; Le Gouill, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, P; Stirling, DI | 1 |
| von Mehren, M | 1 |
| Choo, SP; Lim, KH; Ong, SJ; Teo, M; Toh, HC | 1 |
| Hagemeister, FB | 1 |
| Benson, DM; Byrd, JC; Chan, KK; Chen, CS; Chen, P; Farag, SS; Garr, CL; Grever, MR; Hade, EM; Hicks, WJ; Hofmeister, CC; Ji, J; Johnson, AJ; Kraut, EH; Lee, S; Liu, Z; Phelps, MA; Pichiorri, F; Rozewski, DM; Schaaf, LJ; Yang, X | 1 |
| Ramchandren, R | 1 |
| Santos, FP; Verstovsek, S | 1 |
| Moskowitz, AJ | 1 |
| Ogura, M | 1 |
| Falchook, G; Ganesan, P; Janku, F; Kies, M; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Zinner, R | 1 |
| Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Biernacka, M; Borycka, IS; Bujko, M; Błachnio, K; Grygorowicz, MA; Markowicz, S; Nowak, E; Paszkiewicz-Kozik, E; Rymkiewicz, G; Walewski, J | 1 |
| Trenor, CC | 1 |
| Groves, ML; Sponseller, PD; Suresh, KV; Xu, AL | 1 |
| Andrade, DL; Jalalizadeh, M; Reis, LO; Salustiano, ACC | 1 |
8 review(s) available for thalidomide and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Breakthroughs in myeloproliferative neoplasms.
Topics: Animals; Everolimus; Humans; Immunologic Factors; Janus Kinase 2; Myeloproliferative Disorders; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Sirolimus; Thalidomide | 2012 |
Novel agents in Hodgkin lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Sirolimus; Thalidomide | 2012 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Bevacizumab; Clinical Decision-Making; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Interferons; Propranolol; Sildenafil Citrate; Sirolimus; Thalidomide; Vascular Malformations | 2016 |
Spinal screening, malignancy, medical therapy, and surgical correction of deformity in pediatric patients with neurofibromatosis type 1: a systematic review.
Topics: Child; Humans; Kyphosis; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Sirolimus; Spinal Neoplasms; Thalidomide | 2022 |
4 trial(s) available for thalidomide and sirolimus
| Article | Year |
|---|---|
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Interactions; Humans; Lenalidomide; Maximum Tolerated Dose; Multiple Myeloma; Neoplasm Recurrence, Local; Sirolimus; Survival Rate; Thalidomide; Tissue Distribution; Treatment Outcome | 2011 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Sirolimus; Thalidomide; TOR Serine-Threonine Kinases; Young Adult | 2013 |
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Sirolimus; Thalidomide; Treatment Outcome | 2014 |
9 other study(ies) available for thalidomide and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Lenalidomide; Multiple Myeloma; Protein Kinases; Sirolimus; Stromal Cells; Thalidomide; TOR Serine-Threonine Kinases | 2004 |
New therapeutics for soft-tissue sarcomas in adults.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dioxoles; Enzyme Inhibitors; Humans; Protein Kinases; Protein-Tyrosine Kinases; Sarcoma; Sirolimus; Tetrahydroisoquinolines; Thalidomide; TOR Serine-Threonine Kinases; Trabectedin; Vascular Endothelial Growth Factor A | 2007 |
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Phosphorylation; Receptor, ErbB-2; Sirolimus; Stomach Neoplasms; Thalidomide; TOR Serine-Threonine Kinases | 2010 |
Lenalidomide potentiates CD4
Topics: Adult; Aged; B-Lymphocytes; Blood Donors; CD4 Antigens; Cell Proliferation; Cells, Cultured; Female; Humans; Immunologic Factors; Interleukin-2 Receptor alpha Subunit; Lenalidomide; Lymphoma; Male; Middle Aged; Sirolimus; T-Lymphocytes, Regulatory; Thalidomide | 2017 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guérin (BCG).
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; B7-H1 Antigen; BCG Vaccine; CTLA-4 Antigen; Female; Rats; Sirolimus; Thalidomide; Urinary Bladder Neoplasms | 2023 |